arrow
F

Fatima Karzai

national institutes of health
H指数:27
被引数:2,767

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-Term Oncologic Outcomes of Neoadjuvant Tumor-Directed Immunotherapy (PROSTVAC) Before Radical Prostatectomy for Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Trial

局部前列腺癌术前新辅助肿瘤导向免疫疗法(PROSTVAC)的长期肿瘤学结果:一项新辅助试验的二次分析

2026-09-300
PRE
The quadruple immunotherapy for colorectal cancer (QuICC) trial for mismatch repair-proficient metastatic colorectal cancer

针对错配修复 proficient 的转移性结直肠癌的四联免疫疗法(QuICC)试验

2026-03-012
PRE
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion

雄激素剥夺介导的AKT激活在TMPRSS2:ERG融合的前列腺癌中增强

2025-12-010
OA
Localized high-risk prostate cancer harbors an androgen receptor activity-low subpopulation susceptible to HER2 inhibition

局部高危前列腺癌包含一个雄激素受体活性低的易受HER2抑制的亚群

2025-11-171
OA
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer

阐明靶向MCL1的分子分层单药及联合治疗策略,以治疗致命性前列腺癌

2025-10-080
OAAI
Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023)

癌症临床试验中与FDA药物审批相关的患者入组标准及基线特征(2009–2023)

2025-06-260
OA
PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)

前列腺癌生化复发(BCR)且未接受雄激素剥夺治疗(ADT)的患者在免疫疗法后的PSA应答和PSMA扫描变化

2024-09-010
PRE
Results from the quick efficacy seeking trial (QuEST1) arm combining BN-brachyury (BNVax) plus bintrafusp alfa (BA) plus nogapendekin alfa inbakicept-pmln (N-803) in castration-resistant prostate cancer (CRPC)

卡卢他法(BN-brachyury, BNVax)联合贝兰他法(bintrafusp alfa, BA)以及诺加肽(nogapendekin alfa inbakicept-pmln, N-803)在去势抵抗性前列腺癌(CRPC)的快速疗效探索试验(QuEST1)分支中的结果

2024-09-010
PRE
Performance status restrictions in clinical trials leading to US food and drug administration (FDA) drug approval: A cross-sectional study of a decade (2014-2023)

临床 trials 中 performance status 限制与 US food and drug administration (FDA) 药物审批的关系:一项跨越十年(2014-2023)的横断面研究

2024-09-010
PRE